References

  1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995 Dec 14;333(24):1581-7. PubMed | Google Scholar

  2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA. 4 oct 1995;274(13):1017-25. PubMed | Google Scholar

  3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 45 hours after acute ischemic stroke. N Engl J Med. 25 sept 2008;359(13):1317-29.1. PubMed | Google Scholar

  4. Stroke| introduction| Guidance and guidelines| NICE (Internet). Disponible sur https://www.nice.org uk/guidance/cg68/chapter/introduction. Google Scholar

  5. AVC prise en charge précoce - Recommandations [Internet]. Disponible sur http://www.hassante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti jsp?id=c_830201. Google Scholar

  6. Haley EC, Lyden PD, Johnston KC, Hemmen TM, TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. mar 2005;36(3):607-12. PubMed | Google Scholar

  7. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A Randomized trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine. 22 mars 2012;366(12):1099-107. PubMed | Google Scholar

  8. Logallo N, Kvistad CE, Nacu A, Naess H, Waje-Andreassen U, Asmuss J et al. The norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs alteplase in acute ischaemic stroke. BMC Neurology. 15 may 2014;14(1):106. PubMed | Google Scholar

  9. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al. Classification of subtype of acute ischemic stroke Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke. janv 1993;24(1):35-41. PubMed | Google Scholar

  10. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA: the OSF stroke network experience. Stroke. 2000 Jan;31(1):77-81. PubMed | Google Scholar

  11. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study. JAMA. 2000 Mar 1;283(9):1145-50. PubMed | Google Scholar

  12. Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology. 25 oct 2005;65(8):1169-74. PubMed | Google Scholar

  13. Padma MV, Singh MB, Bhatia R, Srivastava A, Tripathi M, Shukla G, et al. Hyperacute thrombolysis with IV rt-PA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India. mars 2007;55(1):46-9. PubMed | Google Scholar

  14. Wasserman S, Bryer A. Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary care centre. S Afr Med J. juin 2012;102(6):541-4. PubMed | Google Scholar

  15. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin Neurol Neurosurg. 2006 Sep;108(6):549-52. PubMed | Google Scholar